News from Aurora Capital:

Xintria Pharmaceutical Corporation:

Over the past several months, Aurora has assisted in the formation and initial financing of Xintria Pharmaceutical Corporation. Xintria was formed in May 2006 and licensed intellectual property rights from the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences for therapeutic uses of a compound (along with analogs, derivatives and reformulations of that compound) that is on the market in China for an indication other than those of interest to Xintria. Aurora was instrumental in the license negotiations, assessment and protection of the intellectual property, hiring the executive management team, formation of the Board of Directors, , due diligence and writing of the business plan. Two principals of Aurora are executive officers of Xintria and members of the Board of Directors.

General:

Over the past decade Aurora has successfully provided expertise and value added services to the life sciences markets.

For the past year management has dedicated efforts and resources to the strategic advancement of the firm and its capabilities.

Providing quality and focused full-service investment banking, strategic consulting and investment and brokerage services.

Please visit this page in the future for news from Aurora Capital.